PROTEOMICS - Clinical Applications
Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Edited By: Michael J. Dunn
Impact Factor: 2.925
ISI Journal Citation Reports © Ranking: 2012: 29/75 (BIOCHEMICAL RESEARCH METHODS)
Online ISSN: 1862-8354
Associated Title(s): PROTEOMICS
Last update: Decmber 2013
OverviewInstructions and Forms
Style of References
Conflict of Interest Statement
Online Submission of Manuscripts
Wiley-Blackwell policy regarding the NIH mandate
Instructions and FormsTo ensure fast publication we kindly ask you to follow our Instructions to Authors when preparing your manuscript. Please return both Agreement forms as soon as your manuscript has been accepted.
Instructions to Authors (html)
Instructions to Authors (pdf)
Color and Page Charge Agreement (pdf)
Should authors who are not native English speakers have problems writing their papers, assistance is available with style, grammar and vocabulary. Improvement of the English can maximize the accuracy of the submission and help to communicate clearly and concisely the contents to the readers, editors and reviewers of Proteomics Clinical Applications.
Please note: Wiley provides a new professional language and manuscript editing service.
English Language Editing
For detailed information and instructions please go to:
Japanese authors can also find a list of local English improvement services at www.wiley.co.jp/journals/editcontribute.html.
Style of ReferencesThe PROTEOMICS - Clinical Applications reference style is included in EndNote as well as other referencing programs. Authors may choose the program they are most comfortable with. However they must ensure that all information needed is included in the submitted manuscript
Further details and reference examples can be found in the Instructions to Authors.
Conflict of Interest StatementAll authors must declare financial/commercial conflicts of interest. Even if there are none, this should be stated in a separate paragraph following on from the acknowledgements section. This is a mandatory requirement for all articles.
Online Submission of ManuscriptsPROTEOMICS - Clinical Applications offers a web-based manuscript submission and peerreview system. Using this system is obligatory; conventional submission of manuscripts is not accepted.
If you have any questions concerning the online submission, do not hesitate to contact Editorial Support at
Research articles up to 7 printed pages, review articles up to 15 printed pages, and rapid communications, technical briefs, dataset briefs and reports up to 4 pages, are free of charge. For each additional page beyond these limits, the corresponding author will be charged 196 EUR +VAT.
To calculate the number of printed pages your manuscript will have, count the number of text pages, tables and figures and divide the total by three. This will give you a rough estimate.
No page charge will be levied for viewpoint articles and standardisation & guidelines articles.
We do ask our authors to contribute towards the extra costs incurred for the reproduction of color in print.
The prices (excl. VAT) are listed below.
|1 color figure||500.00 Euro|
|2 color figures||832.00 Euro|
|3 color figures||1248.00 Euro|
|4 color figures||1664.00 Euro|
For 5 and more color figures please contact our Production Department for an individual offer at: email@example.com
Reprint PermissionsPlease note that if you are submitting material which has already been published elsewhere, you must also send to the Editorial Office permission in writing that this material may be reprinted in PROTEOMICS - Clinical Applications.
You can use the Copyright Permission Request Form (pdf) for this purpose.
If you want to request permission to use material published by Wiley you can use our Online Permission Request From.
Wiley-Blackwell policy regarding the NIH mandateWiley-Blackwell will support our authors by posting the accepted version of articles by NIH grant-holders to PubMed Central upon acceptance by the journal. The accepted version is the version that incorporates all amendments made during peer review, but prior to the publisher's copy-editing and typesetting. This accepted version will be made publicly available 12 months after publication. The NIH mandate applies to all articles based on research that has been wholly or partially funded by the NIH and that are accepted for publication on or after April 7, 2008.
The NIH has also announced a Request For Information (RFI) process, and we encourage our journal editors and society partners to participate in this. During this process, Wiley-Blackwell will also consult directly with authors, editors and society partners to determine how we as their publisher may best support them going forward.
Wiley-Blackwell also offers a OnlineOpen service. Upon payment of the OnlineOpen fee, we will deposit the published version of the article into PubMed Central, with public availability in PubMed Central and on the journal's website immediately upon publication.
OnlineOpenPROTEOMICS - Clinical Applications offers an OnlineOpen service for all authors. OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, see OnlineOpen Terms.
Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from our website at: https://authorservices.wiley.com/bauthor/onlineopen_order.asp
Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.
Visit Wiley-Blackwell Author Services
A wealth of information for journal authors is now available at http://authorservices.wiley.com.
- Browse journals by subject
- Set up your favorite journals to provide quick links to online submission websites, author guidelines, and more
- Review editorial policies on issues such as ethics, retraction of articles, and more
- Get help for authors whose native language is not English
- View author benefits and rights
- Learn where to order reprints and how to request permission to use copyrighted material
- Claim your 25% author discount on books
- And more…
Instructions to authors
for Proteomics Clinical Applications
Authors are requested to follow these Instructions carefully. Manuscripts not prepared accordingly may be rejected without review. These represent the minimal requirements in order to ensure that a manuscript can be evaluated critically by any reader. Further relevant points may also be found in other published guidelines of good practice as appropriate, for example, for biomarker studies, the STARD (http://stard-statement.org/) and REMARK (http://www.cancerdiagnosis.nci.nih.gov/assessment/progress/remark.htm) guidelines cover relevant factors in their design and reporting.
1 Aims and scope
2 Terms of publication
3 Online submission of manuscripts
4 Types of contributions
5 Specific guidelines for content of clinical proteomics manuscripts
6 Manuscript lengths, figures and page/figure charges
7 Manuscript format
8 Proofs and reprints
9 Open Access
10 Standard abbreviations
1 Aims and scopeProteomics Clinical Applications is a premier source of information in the field of applying proteomics to the study of human disease and translation to the clinic. The journal publishes papers in all relevant areas including basic proteomic research designed to further understand the molecular mechanisms underlying dysfunction in human disease, the results of proteomic studies dedicated to the discovery and validation of disease biomarkers, the use of proteomics for the discovery of novel drug targets, the application of proteomics in the drug development pipeline and the use of proteomics as a component of clinical trials.
Proteomics Clinical Applications is published in 12 issues per year, including regular issues as well as topical issues.
2 Terms of publication
2.1 Copyright policy
If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services, where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.
For authors signing the copyright transfer agreement If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below: CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp.
For authors choosing OnlineOpen If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):
- Creative Commons Attribution License OAA
- Creative Commons Attribution Non-Commercial License OAA
- Creative Commons Attribution Non-Commercial -NoDerivs License OAA
- Imperial College London
- FWF Austrian Science Fund
- Telethon Italy
- University of Nottingham
- UKPMC funders: http://ukpmc.ac.uk/funders/ .
NIH Public Access Mandate
Proteomics Clinical Applications is fully compliant with NIH requirements and Wiley-Blackwell will, as a service to its authors, upload all required files to PubMedCentral. You, as an author, do not need to upload any files. For further information, please visit http://authorservices.wiley.com/bauthor/NIH_policy.asp
Howard Hughes Medical Institute authors
The Howard Hughes Medical Institute (HHMI) and Wiley-Blackwell have agreed to make post-peer reviewed author manuscripts of articles funded by HHMI publicly available six months following final publication. This policy will be implemented for those articles published after October 1, 2007. This arrangement requires nothing of the grantee; identification and deposit are the responsibility of the publisher.
2.2 Cover letter
Manuscripts must be accompanied by a cover letter from the corresponding author. By submitting this letter, the corresponding author accepts responsibility for all statements contained within it.
Every cover letter must contain clear statements covering all the following points:
- The list of the coauthors includes all appropriate persons, and all persons listed have contributed in some way to the design, implementation and/or analysis, interpretation and reporting of the study. Provision of clinical samples, for example, with no other input, does not constitute justification for inclusion as an author.
- All coauthors have seen a draft copy of the manuscript and agree with its publication.
- The work has not been published elsewhere, either completely, in part, or in any other form (with the exception of a meeting abstract) and the manuscript is not currently being considered by another journal.
- The manuscript does/does not contain experiments using animals. The permission of the national or local authorities (giving the permission or the accreditation number of the laboratory and of the investigator) should be stated if animal experiments are included. Permission statements should also be included in the text of the manuscript. If no such rules or permissions have been implicated in the particular country, this must be stated in the cover letter.
- The manuscript does/does not contain human studies. If such studies are included, it should be stated that local Ethical Committee approval was received for the studies and that the informed consent of all participating subjects was obtained. Permission statements relating to this should also be included in the text of the manuscript.
- All funding for the studies in the manuscript, together with the names of the principal funding recipients, are listed in the Acknowledgements.
- Any financial/commercial conflicts of interests have been disclosed. Such conflicts should be detailed in the cover letter and stated in the manuscript after the Acknowledgements.
All scientific contributions are assessed initially by an Associate Editor and/or the Editor-in-Chief. Those manuscripts failing to reach the required priority rating, failing to comply with the Instructions to Authors or not fitting within the scope of the journal are not considered further and are returned to authors without detailed comments. It should be noted that rebuttals that challenge rejections based on priority and/or scope alone will rarely be successful, since such a decision is necessarily a matter of opinion.
Manuscripts meeting the requirements will be peer-reviewed on the criteria of originality and quality. If the decision following review is "reject subject to major revision", a revised version may be submitted, but if major issues with the revised version are still identified by the reviewers, it will then be rejected outright. On acceptance, papers may be subjected to editorial changes. Responsibility for the factual accuracy of a paper rests entirely with the author.
All instances of publishing misconduct, including, but not limited to, plagiarism, data fabrication, image/data manipulation to falsify/ enhance results, etc. will result in rejection/retraction of the manuscript.
This journal endorses the COPE (Committee on Publication Ethics) Code of Conduct and Guidelines and will pursue cases of suspected research and publication misconduct. In such cases, the journal will follow the processes set out by COPE. For more information about COPE please visit the COPE website at http://www.publicationethics.org/.The journal also participates in the new CrossRef service (http://www.crossref.org/crosscheck.html), a plagiarism screening tool that allows the comparison of authored work against the content in the internet database of published work to highlight matching or similar text sections. Please be aware that all manuscripts prior to acceptance will be subject to testing using the CrossCheck software.
Upon acceptance of the manuscript the author is required to fill in the "Copyright Transfer Agreement" and "Color and Page Charge Agreement" forms (please see the journal's For Authors page for current charges), sign them and submit them to:
Proteomics Clinical Applications,
These mandatory forms can also be found on the journal's For Authors page. Please note that if you are submitting material that has already been published elsewhere, you must also send to the Editorial Office permission in writing that this material may be reprinted in Proteomics Clinical Applications. Authors are expected to bear any costs arising from permissions.
All color figures will appear online free of charge.
Our Early View online publication is updated weekly and enables papers to be available online and citable before going into print. The respective DOI (Digital Object Identifier) can be found online.
3 Online submission of manuscriptsSubmission to Proteomics Clinical Applications is via a web-based manuscript submission and peer review system.
3.1 General remarks
Proteomics Clinical Applications publishes articles in English. Manuscripts must be grammatically and linguistically correct, and authors less familiar with English usage are advised to seek the help of English-speaking colleagues. Either American or English spelling is acceptable. Links for English language assistance are available from Author Services at http://authorservices.wiley.com/bauthor/english_language.asp
To submit your manuscript online, please proceed as follows:
- Prepare your manuscript and illustrations in the appropriate format, according to the instructions given below.
- If you have not already done so, create an account for yourself in the system at the submission site
by clicking on the "Create Account" button.
- Let the system guide you through the submission process. Online help is available at all times during the process. You are also able to exit/re-enter at any stage before finally "submitting" your work. All submissions are strictly confidential. To monitor the progress of your manuscript throughout the review process, just log in periodically and check your Author Center.
- To support the review process, you should indicate as “preferred reviewer” two candidates from the journal’s Editors and Members of the Editorial Board whose fields of expertise are closest to the topic of your contribution. For information on the Editors and Members and their respective fields, go to Section 4 of the manuscript submission process. You may suggest up to three more potential reviewers, preferably from outside your own country. Additionally, you may mention non-preferred reviewers.
3.2 Manuscript requirements
Please follow the instructions in Sections 6 and 7 when preparing the electronic version of the manuscript and ensure that data are given in the correct order and style for the journal.
- Main text (including front material) as well as figure legends and tables (in this order) should be given in one file, preferably saved in .doc(x) or .rtf format. Data should be typed unjustified, without hyphenation except for compound words.
- Do not use the space bar to make indents; where these are required use the TAB key.
- If working in Word for Windows, please create special characters through Insert/Symbol.
- Figures should be in TIFF, EPS, PPT or the original format. See Section 6.2 for details.
3.3 Revised manuscripts
In revised manuscripts the areas containing the major required changes should be marked and the script color changed. The file(s) with the changes visible on screen should be submitted to the online procedure. Upon acceptance of the manuscript the final uploaded version will be taken as the basis for copyediting and the subsequent production process.
4 Types of contributionsSeven types of scientific contributions are considered for publication:
(i) Research articles describing complete investigations. Unsolicited research articles should be as concise as possible and about 5000 words in length (including references as well as figure and table legends) and contain no more than five display elements (figures and tables). Manuscripts must not have been published previously, except in the form of a preliminary communication. Research articles should be divided into sections as specified in Section 7.4 below. The authors need to include a separate 200-word statement on "Clinical Relevance" as a separate (unnumbered) section after the title page.
(ii) Review articles are normally invited by the Editor-in-Chief. Authors wishing to submit a review article should send a brief outline of its contents to Prof. Dunn (firstname.lastname@example.org) before the manuscript is drafted. Reviews should not exceed 8500 words (including references as well as figure and table legends) and contain no more than eight display elements (figures and tables). The articles should be divided into sections that are appropriate to the topic.
(iii) Rapid communications describing results that are brief, timely and/or of such importance that rapid publication is warranted. These manuscripts should bear the words "Rapid Communication" immediately above the title on the first page. They should not be subdivided into titled sections but written in a continuous style. Rapid communications should not exceed 2500 words (including references as well as figure and table legends) and contain no more than three display elements (figures and tables). The authors need to include a separate 200-word statement on "Clinical Relevance" as a separate (unnumbered) section after the title page.
(iv) Technical briefs describing the development of a novel method or an improvement or noteworthy modification of an already existing technique or platform used in proteomic analysis. These manuscripts should bear the words "Technical Brief" immediately above the title on the first page. They should not be subdivided into titled sections but written in a continuous style. Technical briefs should not exceed 2500 words (including references as well as figure and table legends) and contain no more than three display elements (figures and tables).
(v) Dataset briefs describing novel proteomic data sets of specific types of samples, such as organisms, tissues, organelles and cells. These data sets can be generated with any proteomic platform including two-dimensional gels, mass spectrometry or protein arrays. An important criterion is that the data set contains a significant number of identified proteins that will benefit further research on that particular sample type. The data set brief format is mandatory for purely descriptive manuscripts (e.g. cataloguing the proteome of a single sample type). The manuscripts should bear the words "Dataset Brief" immediately above the title on the first page. They should not be subdivided into titled sections but written in a continuous style. Data set briefs should not exceed 2500 words (including references as well as figure and table legends) and contain no more than three display elements (figures and tables). Authors are encouraged to submit supporting information, such as annotated two-dimensional gel images and tables of protein identifications, which will only appear online. Deposition of supporting data in a public, open access database like PRIDE (http://www.ebi.ac.uk/pride) or World-2DPAGE (http://world-2dpage.expasy.org/repository/ ) is mandatory.
(vi) Viewpoint articles are intended to stimulate discussion and debate in areas of general concern and controversy in proteomics, and generally reflect the personal opinions of the author(s). These manuscripts should bear the word "Viewpoint" immediately above the title on the first page. They should not be subdivided into titled sections but written in a continuous style. Viewpoint articles should normally not exceed 3500 words (including references as well as figure and table legends) and contain no more than three display elements (figures and tables). Potential authors considering contributing a viewpoint article to the journal should in the first instance contact the Editor-in-Chief by e-mail (email@example.com) to discuss their proposal. In order to provide a forum for debate of the issues raised in the viewpoint articles, correspondence concerning these articles will be published for a special area on the journal's homepage (http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1862-8354/homepage/viewpoint_forum.htm).
(vii) Standardisation & Guidelines articles describing recommendations or best practices on all aspects of proteomics, from experiment planning to data availability. Manuscripts of this type are normally invited by the Editor-in-Chief. Authors wishing to submit a Standardization & Guidelines article should send a brief outline of its contents to Prof. Dunn (firstname.lastname@example.org) before the manuscript is drafted. Standardisation & Guidelines articles should be as concise as possible and should not exceed about 5000 words in length (including references as well as figure and table legends) and contain no more than 5 display elements (figures and tables). Manuscripts must not have been published previously, though previous publicly accessible discussion documents are acceptable. The articles may be divided into sections which are appropriate to the topic.
5 Specific guidelines for content of clinical proteomics manuscriptsTo ensure adequate interpretation and context, it is essential that the following points are clearly addressed in the manuscript as and when appropriate depending on the study type. It is recommended that the term "candidate biomarker" or equivalent such as "potential biomarker" be used to refer to findings of early phase studies when additional validation/qualification is needed.
5.1 Aims of the study
The study aims and clinical relevance in the context of a brief description of the study design and type, e.g. whether pilot, discovery or validation/qualification, etc. should be clearly stated at the end of the Introduction as well as in the Abstract.
5.2 Study design
- A clear and full description of the study design including whether prospective or retrospective should be presented at the beginning of the Materials and methods section. All clinical endpoints examined should be defined, and variables examined/included in the data analysis should be listed.
- The relationship between the patient group(s)/samples used in the different parts of the study should be clear, e.g. biomarker discovery phase versus validation/qualification phases. Independent cohorts are required for the different stages in biomarker studies. Discovery mechanism-based studies are encouraged to include validation. If no validation experiments are provided, then this must be justified in the text.
- The rationale/statistical justification for the numbers of samples used should be provided, for example, if selected on the basis of detecting a specific effect size, the significance level, power and effect size should be stated. One biological replicate is not acceptable, even for cell line-based studies. For further guidance on best practice in statistical reporting please see the article series published by the Physiological Society and the British Pharmacological Society at http://jp.physoc.org/cgi/collection/stats_reporting.
- A statement regarding appropriate Ethical Committee approval must be included and that the informed consent of all participating subjects was obtained. If the manuscript describes experiments using animals, the approval of the national or local authorities (giving the approval or the accreditation number of the laboratory and of the investigator) should be stated. If no such rules or permission are stipulated in the particular country, this must also be mentioned in the paper.
- For reports of studies involving animals, please follow the ARRIVE guidelines which are hosted on the NC3Rs website at http://www.nc3rs.org.uk/ARRIVEpdf.
5.3 Patient groups
- The method of recruitment should be described together with any inclusion and selection/exclusion criteria (e.g. prospective or retrospective, attendance at specific clinic, etc.). The time periods over which recruitment and sample collection took place, together with follow-up periods where relevant for outcome studies, should be provided for each clinical group. Consideration should be given to the most appropriate control group for the specific study aims, for example, whether healthy controls or other disease groups should be used and whether they are representative of the intended eventual use of a potential biomarker.
- For each group, the clinical condition and any categorisation based on disease severity (e.g. stage, grade or clinical scoring system) or subtype (e.g. histological or aetiologic) should be clearly described. Demographic and clinical summary details (preferably in a table) should be provided for each group, including any control subjects, together with any additional relevant lifestyle factors such as type of diet or smoking history.
- Where relevant, any specific procedures used for sample timing, e.g. morning fasted blood sample or first-void urine, should be described. Similarly details of any therapies or a statement that patients were previously untreated at the time of sampling should be provided.
5.4 Clinical samples
- The sources of the different samples should be indicated, for example single centre or multiple centres - in the latter case it should be clear whether samples from the different clinical groups/subgroups were provided by different centres.
- Full details of sample processing should be given. A statement should be provided as to whether these conditions were the same for all samples and any differences between groups described. For fluids this should include method and volume of collection, tube types and any additives, processing times and temperatures, centrifugation conditions and storage conditions (storage duration, temperature and any freeze-thaw cycles). For tissues, this should include method of collection, block sizes, processing times and conditions including delay to fixation/freezing, type of fixation and details of any histological review.
5.5 Sample analysis
- The proteomic methods used to analyze the samples should be described with a level of stringency and detail to allow repetition by other scientists, including any manipulation of samples prior to analysis. Provision of information relating to gel electrophoresis, mass spectrometry and other techniques in accordance with the more detailed "Minimum Information About a Proteomics Experiment" recommendations (http://www.psidev.info/MIAPE/) is strongly encouraged.
- The design of the analysis process should be described, for example, technical and biological replicate number, method and type of randomisation, technical controls used, time span of sample analysis and whether undertaken with the operator blinded to sample status.
- Relevant details of key technical aspects of the analytical processes such as inter- and intra-experimental variation, normalisation, sensitivity and specificity (with regard to the analyte), lower and upper limits of detection, should be provided as appropriate to the technology being used. Any experimental quality control processes should be described, such as use of statistical QC analysis procedures or inclusion of positive and negative controls, for example. Similarly, for reagents such as antibodies, details of the characterisation in terms of specificity should be provided or a citation provided.
- For label and label-free methods the authors should include technical controls and state the number of technical replicates and also false positive rates.
- For any algorithmic pattern or recognition-based profiling approaches where the protein/peptide identities of the key determinants are not known, analysis must be reproducible and replicated on an independent test set. The pattern must also be shown to be stable and reproducible over time.
5.6 Protein identification and characterisation
- Authors should adhere to the Paris guidelines (http://www.mcponline.org/misc/ParisReport_Final.dtl).
- The method(s) used to generate the mass spectrometry data must be described, including the methods used to create peak lists from raw MS or MS/MS data.
- The name and version of the program(s) used for database searching, the values of critical search parameters (e.g. parent ion and fragment mass tolerance, cleavage rules used, allowance for number of missed cleavages) and the name and version of the database(s) searched must be provided.
- For each protein identified, measures of certainty (e.g. p-values) must be provided. For MS/MS, the number of peptides used to identify a protein must be given as well as the sequence and charge state of each peptide. For peptide mass fingerprinting, the number of peptides that match the sequence and the total percent of sequence coverage must be quoted. If extensive, the above information should be collected as supporting information, which is available online.
- Identifications based on at least two significant peptides is encouraged. However, if single peptides are used, MS spectra must be supplied as supporting information and confirmed manually.
- Protein name clustering should be used to reduce protein name redundancy.
- For experiments with large MS/MS data sets, estimates of the false positive rates are required (e.g. through searching randomized or reversed sequence databases). This information should be provided as supporting information.
- Where post-translational modifications are reported, the methods used to discover the modification must be described. The modification should be mapped to amino acid(s) by fragmentation analysis, but reported as ambiguous if mapping to a single amino acid is not possible. For isobaric or other stable chemical labeling modifications, evidence for assigning a specific modification must be provided and the spectra included as supporting information.
- Where protein sequence isoforms are reported, the peptide sequence that matches the unique amino acid sequence of a particular isoform must be provided. Fragmentation analysis of the appropriate peptides must be described.
- If a proteomics experiment reports a protein that is an enzyme, then relevant data to describe the enzyme should follow the standards for reporting enzymology data (STRENDA). For details see the Beilstein Institut/STRENDA website at http://www.beilstein-institut.de/en/projekte/strenda/guidelines.
5.7 Data analysis
- Full details of any software, bioinformatic tools or image capture processes used for data processing or analysis should be provided. Where a manuscript describes an academic database or software, it must be freely accessible for review, either through a web interface, or for download and local installation of (minimally) a functional test version. This also applies to commercial software or databases. Deposition of supporting data in a public, open access database like PRIDE (http://www.ebi.ac.uk/pride) or World-2DPAGE (http://world-2dpage.expasy.org/repository/ ) is strongly recommended, and mandatory for Dataset Briefs.
- The specific hypotheses being tested should be clearly described. Any statistical tests should be fully described with relevant summary statistics, p-values and confidence intervals being given and consideration given to corrections for multiple testing as appropriate. Many investigations/submissions can benefit from the consultation of a professional statistician to aid in experimental design, analysis and appropriate result reporting, and this is strongly encouraged. For example, for diagnostic biomarkers, scatter plots of data, sensitivity and specificity values with confidence intervals and results of receiver operating characteristic curve analysis should be given, as a minimum. The number of patients and the variables included at each stage of the analysis must be clearly described and reasons and support for dropout/exclusion provided. If a marker is already routinely used as a "gold standard" for that disease and clinical scenario, comparison with the performance of that marker should be included.
- Any manipulation of data such as data normalization, transformation or handling of missing values should be clearly described. Similarly, variables included in any multiple regression analysis should be indicated.
- Factors considered and included in the analyses as potentially confounding should be listed.
- Selection of specific technical cut-offs for quantitative or qualitative analyses (e.g. proteins differing by >2-fold) and statistical thresholds for evaluation of biomarker utility should be justified. Where reference ranges are used, details of the reference population and how the range was derived should be provided.
5.8 Data validation
- In comparative or shotgun-like discovery studies, some confirmatory data (e.g. from validated immunoassays, immunohistochemistry, alternative MS-based methods, Western blotting, etc.) are required using independent replication sets for at least a subset of proteins. If no validation experiments are provided, then this must be justified in the text.
- Where models are generated based on a training set, validation results from an independent test set or some form of bootstrapping/ cross-validation should also be included.
- Where the output of the study is a model generated without knowledge of protein/peptide identity, for example, mass spectra or gel patterns/algorithms, the reproducibility and hence utility of the findings should be demonstrated over a prolonged time period using that experimental platform.
5.9 Data interpretation
- In the Discussion, the results must be interpreted and discussed in the context of the defined aims and purpose of the study and other relevant published literature.
- Any possible limitations of the study must be described and discussed and insight should be provided into the future implications of the findings.
6 Manuscript lengths, figures and page/figure charges6.1 Manuscript length and page charges
Articles should conform to the following length restrictions:
- Research articles - seven printed pages (∼5000 words and no more than five display elements)
- Review articles - 15 printed pages (∼8500 words and no more than eight display elements)
- Rapid communications - four printed pages (∼2500 words and no more than three display elements)
- Technical briefs - four printed pages (∼2500 words and no more than three display elements)
- Dataset briefs - four printed pages (∼2500 words and no more than three display elements)
- Viewpoint articles - six printed pages (∼3500 words and no more than three display elements)
- Standardisation & Guidelines articles - seven printed pages (∼5000 words and no more than five display elements)
Please prepare your figures according to the following guidelines:
- Each figure should be given in a separate file and should have the following resolution at their final published size:
Type Resolution Graphs 800-1200 DPI Photos 400-800 DPI Color (only RGB) 300-400 DPI
- Monochrome art (black on white) should be in ‘bitmap’ mode (also called 1-bit). Grayscale art should be in ‘grayscale’ mode, a palette of colors that has 256 shades ranging from white to black (also called 8-bit). Colour art should be in RGB mode. RGB stands for Red, Green and Blue – these are the colors that are displayed by computer monitors. For details please go to http://authorservices.wiley.com/electronicartworkguidelines.pdf
- Use the zoom function to check the resolution of the figures: if an image viewed at 400% on screen is blurry (pixellated), then the image will not reproduce well in print. An image viewed at 100% on screen may look fine but will not necessarily reproduce well as the screen resolution is much lower (72-96 dpi) than that of a printing press.
- Crop, or scale, figures to the size intended for publication; no enlargement or reduction should be necessary. Otherwise figures should be submitted in a format that can be reduced to a width of 50-80mm or 120-170mm, with symbols and labels to a height of 2.0mm (after reduction) and a minimum line weight of 0.3 pt for black lines.
- Photographic images often produce large files. Most software has an option to use LZW compression and this will produce smaller files, especially when the image contains large areas of single color or repeating textures and patterns.
- In electropherograms presented horizontally, the anode should be on the left while in vertical presentations the anode should be at the bottom. Two-dimensional presentations, e.g. with isoelectric focusing and sodium dodecyl sulfate electrophoresis in the two dimensions, are thus presented consistently with the standard coordinate system.
- Figures should be numbered consecutively with Arabic numerals in the order of their appearance.
- Each figure is to be accompanied by a legend that should be self-explanatory. The legends should not appear under the figures but be included after the references.
6.3 Color charges
While all color figures will appear online free of charge, authors will be charged for additional costs incurred for the reproduction of color in print (see Section 2).
7 Manuscript formatManuscripts must be typewritten with double spacing throughout (including references, legends, etc.).
7.1 Title page
The first page of all manuscripts should contain only the following:
(i) Title of the paper - standard abbreviations may be used in the title.
(ii) Full names (including first name) of the authors and the name of the institute. If the publication originates from several institutes the affiliations of all authors should be clearly stated by using superscript numbers after the name and before the institute.
(iii) Name (and title) and full postal address of the author to whom all correspondence (including galley proofs) is to be sent. Email, address and fax number must be included to speed up communication.
(iv) A list of abbreviations used in the paper excluding standard abbreviations (see list of "Standard Abbreviations", Section 10).
(v) Keywords (max. five, in alphabetical order).
(vi) Total number of words (including references as well as figure and table legends).
7.2 Statement of clinical relevance
On the page immediately after the title page, a statement describing the potential clinical significance of the study in terms of clinical need, goals and how the study moves the field forward should be provided (max. 200 words). This does not apply to review and viewpoint articles.
The third page of the manuscript should contain the abstract only. For research articles, rapid communications, technical briefs and dataset briefs, it should be structured as follows:
Conclusions and clinical relevance
The abstract should not exceed 200 words. Non-standard abbreviations must be written in full when first used and the abstract should not contain any references.
7.4 Sections in research articles
Research articles should be divided into the following sections and include the information required in the guidelines in Section 5:
"1 Introduction" containing a description of the problem under investigation and a brief survey of the existing literature on the subject before ending with a brief summary of the aims of the study in the context of the study design.
"2 Materials and methods" providing an outline of the experimental design of the study. The main methodological steps should be described and, where possible, references to previously published methods provided. Special materials and equipment, the manufacturer's name and location should also be indicated. The section should be understandable as a standalone text. Any further experimental details can be placed in supporting information.
Sections 3 and 4 may be combined and should then be followed by a short section entitled "Concluding remarks". Subdivisions of sections should be indicated by numbered subheadings.
References should be numbered sequentially in the order in which they are cited in the text. The numbers should be set in brackets thus [2, 18]. References are to be collected in numerical order at the end of the manuscript under the heading "References"; they should also be typed with double spacing throughout. Papers with multiple authors should be limited to listing five authors. Where there are more than five authors, the first four should be listed, followed by et al. Please include the title of the manuscript in full followed by a full stop. Journal names should be abbreviated according to the practice of PubMed. The abbreviated title and the volume number should be in italics. Please note the following examples.
 Hu, J., Qian, J., Borisov, O., Pan, S. et al., Optimized proteomic analysis of a mouse model of cerebellar dysfunction using aminespecific isobaric tags. Proteomics 2006, 6, 4321-4334.
 Vosseller, K., Proteomics of Alzheimer's disease: Unveiling protein dysregulation in complex neuronal systems. Proteomics Clin. Appl. 2007, 1, 1351-1361.
Other serial publications such as "Advances in Protein Chemistry" should be cited in the same manner as journals.
 Elves, M. W., The Lymphocytes, Lloyd-Luke Ltd., London 1972.
Chapter in a book:
 Müller, E., Greaves, M. F., in: Mäkelä, O., Cross, A., Kosunen, T. U. (Eds.), Cell Interactions and Receptor Antibodies in Immune Responses, Academic Press, New York 1971, pp. 101-125.
Allusions to "unpublished observations", papers "to be published" or "submitted for publication" and the like should be part of the text, in parentheses. Material "in press" should be entered under references along with the DOI, if available. Posters and abstracts in meetings books must not be cited unless they are generally accessible. Responsibility for the accuracy of bibliographic references rests entirely with the author.
Please note that website addresses must not be included as a reference, but should be inserted in parentheses in the text directly after the data to which they refer.
Authors should provide complete references in as accessible a way as possible, using software that they are most comfortable using.
Acknowledgements as well as information regarding funding sources should be provided on a separate page at the end of the text (before "References").
7.7 Conflict of interest statement
All authors must declare financial/commercial conflicts of interest. Even if there are none, this should be stated as “The authors have declared no conflict of interest” on a separate line following the acknowledgements section. This is a mandatory requirement for all articles.
Tables with suitable captions at the top and numbered with Arabic numerals should be collected at the end of the text on separate pages for different tables. Column headings should be kept as brief as possible and indicate units. Footnotes to tables should be indicated with a), b), c), etc. and typed on the same page as the table.
7.9 Supporting information
For details on data that may be included in the supporting information, go to Author Services at http://authorservices.wiley.com/bauthor/suppinfo.asp.
Extensive tables should be published online as supporting information. This material will not be typeset so authors should prepare this in the final form. Also for this reason there will be no galley proofs of this material. Supporting information will be made freely available on the web (similar to the table of contents and the article abstracts). Authors are permitted to place this material on their homepages when they are setting up a link to the full-text version of the article in Wiley Online Library.
Further, other files may be submitted as supporting information (e.g. animations, video sequences). All supporting information will also undergo the peer-review process. Thus, this material has to be submitted electronically along with the main body of the article. It is in the hands of the Editor-in-Chief to decide which part of the manuscript will be published as supporting information.
Protein identification results, expression data and mass spectrometry peak lists should also be submitted as supporting information, and may be identical to data deposited in a public database. Note that all data must be in processed, not raw, form. Data should be deposited in public, open access databases, formatted according to conventions of the relevant communities prior to manuscript submission, and database accession numbers provided in the manuscript. In particular, novel protein sequences should be deposited in UniProt (http://www.uniprot.org), molecular interactions in an IMEx partner database (http://www.imexconsortium.org), and protein identification data in PRIDE (http://www.ebi.ac.uk/pride), World-2DPAGE (http://www.expasy.org/world-2dpage/) or a comparable database. Where a suitable database does not exist for a particular type of processed data, raw data should be made available through a freely accessible public dissemination system, for example Tranche (https://proteomecommons.org/tranche/).
7.10 Image manipulation
Manipulation of images is unacceptable. All figures must accurately reflect the original data. Information should not be enhanced, eliminated, added, obscured or moved. In cases where manipulation is unavoidable, this should be clearly detailed in the Figure legend. All instruments, software and processes used to obtain the images must be fully detailed in the manuscript either in the Figure legends or the Materials and methods. Acceptable image manipulation includes uniformly adjusting the contrast of an entire image and any control images, ensuring that all original data, including the background, remains visible and that no new features are introduced. Cropping of gels, or re-positioning of lanes/fields, is permitted providing that all alterations are clearly indicated by the use of dividing lines in the image itself, vital data are not removed, an explanation of the alterations is included in the Figure legend and images of full blots or gels that the figures are derived from are supplied in the supporting information. Unacceptable manipulation includes, but is not limited to, the enhancement of one feature/ band over others, removal of background noise/bands, etc. Authors must be able to produce all data in their raw format upon editorial request.
7.11 Structural formulae
Structural formulae should be drawn in the manuscript in the position where they belong. They must be numbered in consecutive order with the other figures.
Mathematical and chemical equations are to be written in the manuscript at the place in which they belong and should be marked by Arabic numerals in parentheses in the right margin in the order of their appearance.
Abbreviations are hindrances to a reader working in a field other than that of the author, and to abstractors. Therefore, their use should be restricted to a minimum. Abbreviations should be introduced only when repeatedly used. Abbreviations used only in a table or a figure may be defined in the legend. Standard abbreviations may be used in the title and keywords. If nonstandard abbreviations are used in the Abstract they should be defined in the Abstract, in the list of abbreviations of the manuscript as well as when first used in the body of the paper.
Section 10 at the end of these instructions contains the list of standard abbreviations that may be used without definition in the articles published in Proteomics Clinical Applications.
7.14 Sharing of materials
All materials and reagents that are not commercially available (antibodies, cell lines, constructs, etc., but not clinical samples) and associated protocols detailed in manuscripts published in Proteomics Clinical Applications are to be freely available to academic researchers in a timely manner upon request. The authors agree to this condition when they submit a manuscript to Proteomics Clinical Applications.
8 Proofs and reprintsBefore publication authors will be sent a link to access their proofs via e-mail together with instructions and a reprint order form. The proofs should be carefully corrected following the instructions. In particular, authors should answer any editing queries. Please return proof corrections as instructed.
Note: Authors will be charged for extensive alterations of their article.
The reprint order form should be filled out (even if additional reprints are not required) and returned by fax to the Editorial office (see Section 2). Upon publication the submitting author (listed under "Correspondence") will receive a complimentary pdf of his/her article.
9 Standard abbreviationsThe abbreviations as listed below may be used without definition in the articles published in Proteomics - Clinical Applications.
|ACES||2-[(2-amino-2-oxoethyl)amino] ethanesulfonic acid|
|A/D||analog to digital converter|
|amu||atomic mass unit|
|ANOVA||analysis of variance|
|API||atmospheric pressure ionization|
|AUC||area under curve|
|BSA||bovine serum albumin|
|%C||cross-linking agent (g/100 mL)/%T|
|CBB||Coomassie Brilliant Blue|
|CFE||continuous flow electrophoresis|
|CHES||2-(N-cyclohexylamino)ethane sulfonic acid|
|CIEF||capillary isoelectric focusing|
|CMC||critical micelle concentration|
|Con A||Concanavalin A|
|CNS||central nervous system|
|cpm||counts per minute|
|CV||coefficient of variation|
|CZE||capillary zone electrophoresis|
|Da||dalton (molecular mass)|
|2DE||two-dimensional gel electrophoresis|
|DIGE||fluorescence difference gel electrophoresis|
|DGGE||denaturing gradient gel electrophoresis|
|DMEM||Dulbecco's modified Eagle medium|
|EGTA||ethylene glycol-bis(β-aminoethylether)-N,N,N',N'-tetraacetic acid|
|ELISA||enzyme-linked immunosorbent assay|
|EST||expressed sequence tag|
|FAB||fast atomic bombardment|
|FBS||fetal bovine serum|
|FCS||fetal calf serum|
|FIGE||field inversion gel electrophoresis|
|FT-ICR||Fourier transform-ion cyclotron resonance|
|GIF||graphic interchange format|
|GRAVY||grand average of hydrophobicity|
|HE||hematoxylin and eosin|
|HPCE||high-performance capillary electrophoresis|
|HPLC||high-performance liquid chromatography|
|HSA||human serum albumin|
|HSP||heat shock protein|
|HTML||hypertext mark-up language|
|HUPO||Human Proteome Organisation|
|ICAT||isotope-coded affinity tag|
|ICR||ion cyclotron resonance|
|IMAC||immobilized metal affinity chromatography|
|IPG||immobilized pH gradient|
|iTRAQ||isobaric tag for relative and absolute quantitation|
|kDa||kilodalton (molecular mass)|
|LOD||limit of detection|
|LOQ||limit of quantitation|
|MALDI-MS||matrix-assisted laser desorption/ionization-mass spectrometry|
|MEKC||micellar electrokinetic capillary chromatography|
|MHC||major histocompatibility complex|
|Mr||relative molecular mass (dimensionless)|
|MS/MS||tandem mass spectrometry|
|NEPHGE||nonequilibrium pH gradient electrophoresis|
|NMR||nuclear magnetic resonance|
|OFAGE||orthogonal field alternation gel electrophoresis|
|ORF||open reading frame|
|PAGE||polyacrylamide gel electrophoresis|
|PCA||principal components analysis|
|PCR||polymerase chain reaction|
|PED||pulsed electrochemical detection|
|PFGE||pulsed-field gel electrophoresis|
|PMF||peptide mass fingerprinting|
|PRIDE||PRoteomics IDEntifications database|
|RFLP||restriction fragment length polymorphism|
|ROS||reactive oxygen species|
|rpm||revolutions per minute|
|RSD||relative standard deviation|
|SAGE||serial analysis of gene expression|
|SDS||sodium dodecyl sulfate|
|SELDI||surface-enhanced laser desorption/ionization|
|SEM||standard error of the mean|
|SILAC||stable isotope labelling with amino acids in cell culture|
|SIM||selected ion monitoring|
|SPR||surface plasmon resonance|
|SSCP||single-strand conformation polymorphism|
|SSP||sample spot number|
|STR||short tandem repeat|
|%T||total gel concentration (acrylamide plus cross-linking agent; g/100mL)|
|TIC||total ion current|
|TOF||time of flight|
|URL||uniform resource locator|